Bayspair's original CRISPR

Bayspair has developed a proprietary engineered nuclease to replace CRISPR/Cas9. As with conventional techniques, it is possible to destroy or insert sequences at targeted sites with guide RNA. The rights to this nuclease are 100% owned by Bayspair and can be licensed for all areas including research applications as well as industrial and clinical applications for therapeutics. All genome editing services offered by Bayspair use this nuclease system. Therefore, the cells created by Bayspair will not be limited in their use by licensing issues with third party genome editing technologies.

Knock-out

The introduction of nuclease and guide RNA into cells causes sequence deletions via non-homologous end joining (NHEJ) or microhomology mediated end joining (MMEJ). Fewer single nucleotide insertion events and relatively large sequence deletions compared to CRISPR/Cas9 (probably due to predominance of MMEJ-mediated editing)

Knock-in

By introducing donor DNA in addition to nucleases and guide RNA, the sequence flanked by the homology arms of the donor DNA is inserted through homology directed repair (HDR) pathway at a lower probability than with knockout.